178 related articles for article (PubMed ID: 22532520)
1. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
Caballero-Velázquez T; Sánchez-Abarca LI; Gutierrez-Cosio S; Blanco B; Calderon C; Herrero C; Carrancio S; Serrano C; del Cañizo C; San Miguel JF; Pérez-Simón JA
Haematologica; 2012 Sep; 97(9):1329-37. PubMed ID: 22532520
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Sun K; Li M; Sayers TJ; Welniak LA; Murphy WJ
Blood; 2008 Aug; 112(4):1522-9. PubMed ID: 18539902
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.
Weng J; Lai P; Lv M; Lin S; Ling W; Geng S; Luo C; Liu X; Du X
Clin Lab; 2013; 59(1-2):51-8. PubMed ID: 23505906
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
5. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease.
Li Z; Wu Q; Yan Z; Li D; Lu G; Mou W; Wu S; Pan X; Lu Q; Xu K
Transplant Proc; 2013; 45(6):2527-35. PubMed ID: 23953575
[TBL] [Abstract][Full Text] [Related]
6. The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.
Li M; Sun K; Redelman D; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):739-50. PubMed ID: 20338256
[TBL] [Abstract][Full Text] [Related]
7. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
[TBL] [Abstract][Full Text] [Related]
8. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
11. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
Blanco B; Pérez-Simón JA; Sánchez-Abarca LI; Carvajal-Vergara X; Mateos J; Vidriales B; López-Holgado N; Maiso P; Alberca M; Villarón E; Schenkein D; Pandiella A; San Miguel J
Blood; 2006 May; 107(9):3575-83. PubMed ID: 16282346
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma.
Truitt RL; Shih CC; LeFever AV
Transplantation; 1986 Mar; 41(3):301-10. PubMed ID: 3513389
[TBL] [Abstract][Full Text] [Related]
16. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
17. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
18. IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
Liang Y; Ma S; Zhang Y; Wang Y; Cheng Q; Wu Y; Jin Y; Zheng D; Wu D; Liu H
J Immunol; 2014 Feb; 192(3):1277-85. PubMed ID: 24363427
[TBL] [Abstract][Full Text] [Related]
19. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
20. Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1996 May; 17(5):789-92. PubMed ID: 8733699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
